Navigation Links
Insmed to Present at Biosimilars 2008 Conference
Date:9/15/2008

RICHMOND, Va., Sept. 15 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at the Biosimilars 2008 Conference in Washington D.C. Dr. Allan will be discussing the Company's perspective on the potential impact of follow-on biologics (FOB) on American consumers and will also Chair a panel on this topic on Tuesday, September 23, 2008 in the Jack Morton Auditorium at George Washington University in Washington, D.C. Dr. Allan's presentation will take place at 9:55 AM ET and the panel discussion will begin at 11:25 AM ET.

Biosimilars 2008 is a two day conference focusing on the need for and applications of FOB, with an emphasis on issues surrounding the possible establishment of a defined regulatory pathway for FOB.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed to Present at BioPharm Asia 2008 Conference
2. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
3. Insmed CEO to Present at Drug Discovery & Development Conference
4. Insmed to Host Second Quarter 2008 Conference Call
5. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
6. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
7. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
8. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
9. Insmed Announces First Quarter 2008 Financial Results
10. Insmed to Present at CBI Follow-On Biologics Conference
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 2017 , ... The Academy of Model Aeronautics (AMA) will ... 2017, to promote AMA’s programs, member services, and the model aviation hobby. The ... not limited to model aviation and other RC activities. , Thousands are expected ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... client portal. Each relaunch of the portal includes new features that facilitate streamlined ... device companies seek to remain at the forefront of medical advancements, they rely ...
(Date:9/21/2017)... ... 21, 2017 , ... Biorez, Inc. , a regenerative ... Entrepreneur in Residence at Medtronic, Inc., to serve as an Independent Director on ... for anterior cruciate ligament (ACL) reconstruction that is designed to stabilize the knee ...
(Date:9/20/2017)... ... 20, 2017 , ... Proscia Inc. , a data ... of whole slide imaging solutions, are hosting a pre-conference workshop at the ... a Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, David West Jr., ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
Breaking Biology News(10 mins):